Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Neoplasms | 19 | 2024 | 9213 | 0.890 |
Why?
|
Magnetic Resonance Imaging | 29 | 2024 | 36854 | 0.890 |
Why?
|
Glioblastoma | 11 | 2019 | 3525 | 0.850 |
Why?
|
Posterior Leukoencephalopathy Syndrome | 1 | 2023 | 50 | 0.820 |
Why?
|
Guillain-Barre Syndrome | 1 | 2023 | 127 | 0.770 |
Why?
|
Spectrum Analysis, Raman | 3 | 2014 | 253 | 0.540 |
Why?
|
Epilepsy | 2 | 2022 | 3326 | 0.530 |
Why?
|
Image Interpretation, Computer-Assisted | 7 | 2024 | 3411 | 0.520 |
Why?
|
Diffusion Magnetic Resonance Imaging | 5 | 2018 | 2831 | 0.460 |
Why?
|
Astrocytoma | 2 | 2015 | 781 | 0.430 |
Why?
|
Histocytological Preparation Techniques | 1 | 2012 | 33 | 0.410 |
Why?
|
Tomography, X-Ray Computed | 5 | 2017 | 20776 | 0.380 |
Why?
|
Perfusion Imaging | 1 | 2013 | 196 | 0.370 |
Why?
|
Glioma | 6 | 2024 | 3532 | 0.370 |
Why?
|
Cell Tracking | 1 | 2012 | 140 | 0.370 |
Why?
|
Multiple System Atrophy | 2 | 2022 | 132 | 0.360 |
Why?
|
Head | 1 | 2017 | 927 | 0.360 |
Why?
|
Cranial Fossa, Posterior | 1 | 2011 | 134 | 0.350 |
Why?
|
Creutzfeldt-Jakob Syndrome | 3 | 2006 | 92 | 0.350 |
Why?
|
Adenoma | 2 | 2011 | 2163 | 0.330 |
Why?
|
Ciliary Body | 1 | 2009 | 168 | 0.320 |
Why?
|
Echo-Planar Imaging | 2 | 2014 | 674 | 0.310 |
Why?
|
Radiation Dosage | 1 | 2017 | 1970 | 0.300 |
Why?
|
Neuronavigation | 1 | 2009 | 169 | 0.300 |
Why?
|
Contrast Media | 2 | 2017 | 5334 | 0.290 |
Why?
|
Mesencephalon | 1 | 2009 | 339 | 0.290 |
Why?
|
Nervous System Diseases | 1 | 2017 | 1665 | 0.280 |
Why?
|
Uveal Neoplasms | 1 | 2009 | 344 | 0.270 |
Why?
|
Cerebrovascular Disorders | 1 | 2013 | 1486 | 0.260 |
Why?
|
Blood Flow Velocity | 1 | 2009 | 1376 | 0.240 |
Why?
|
Image Enhancement | 5 | 2012 | 2898 | 0.230 |
Why?
|
Dacarbazine | 3 | 2015 | 559 | 0.230 |
Why?
|
Brain | 14 | 2022 | 27453 | 0.230 |
Why?
|
Critical Care | 1 | 2017 | 2716 | 0.230 |
Why?
|
Pregnancy Complications | 1 | 2017 | 2974 | 0.220 |
Why?
|
Skin | 2 | 2017 | 4506 | 0.220 |
Why?
|
Pituitary Neoplasms | 1 | 2011 | 1326 | 0.200 |
Why?
|
Supranuclear Palsy, Progressive | 1 | 2022 | 82 | 0.200 |
Why?
|
Antibodies, Monoclonal | 2 | 2017 | 9264 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2019 | 9442 | 0.180 |
Why?
|
Deep Brain Stimulation | 1 | 2009 | 851 | 0.180 |
Why?
|
Immunotherapy | 1 | 2017 | 4756 | 0.180 |
Why?
|
Pattern Recognition, Automated | 3 | 2012 | 998 | 0.170 |
Why?
|
Tomography, Optical Coherence | 1 | 2012 | 2957 | 0.160 |
Why?
|
Cerebrovascular Circulation | 1 | 2009 | 2734 | 0.150 |
Why?
|
Parkinson Disease | 2 | 2022 | 2895 | 0.150 |
Why?
|
Angiography, Digital Subtraction | 1 | 2019 | 332 | 0.150 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2019 | 126 | 0.150 |
Why?
|
Algorithms | 8 | 2012 | 14201 | 0.150 |
Why?
|
Antineoplastic Agents | 3 | 2019 | 13698 | 0.150 |
Why?
|
Sarcoma | 1 | 2008 | 1806 | 0.140 |
Why?
|
Sensitivity and Specificity | 8 | 2020 | 14752 | 0.140 |
Why?
|
Humans | 48 | 2024 | 768970 | 0.140 |
Why?
|
Uncertainty | 1 | 2021 | 769 | 0.140 |
Why?
|
Morpholines | 1 | 2019 | 584 | 0.130 |
Why?
|
Tomography, Spiral Computed | 1 | 2017 | 274 | 0.120 |
Why?
|
Disease-Free Survival | 4 | 2015 | 6856 | 0.120 |
Why?
|
Aminopyridines | 1 | 2019 | 580 | 0.120 |
Why?
|
Brain Mapping | 4 | 2019 | 6739 | 0.110 |
Why?
|
Middle Aged | 21 | 2024 | 223737 | 0.110 |
Why?
|
Female | 27 | 2024 | 397515 | 0.100 |
Why?
|
Survival Rate | 3 | 2017 | 12873 | 0.100 |
Why?
|
Male | 22 | 2024 | 365203 | 0.100 |
Why?
|
Area Under Curve | 1 | 2015 | 1645 | 0.090 |
Why?
|
Adult | 21 | 2024 | 223851 | 0.090 |
Why?
|
Reproducibility of Results | 7 | 2013 | 20245 | 0.090 |
Why?
|
Preoperative Care | 2 | 2011 | 2258 | 0.090 |
Why?
|
Diagnosis, Differential | 7 | 2022 | 13021 | 0.090 |
Why?
|
Retrospective Studies | 11 | 2022 | 81903 | 0.090 |
Why?
|
Public Health | 1 | 2024 | 2680 | 0.090 |
Why?
|
Induced Pluripotent Stem Cells | 1 | 2022 | 1891 | 0.090 |
Why?
|
Stroke | 2 | 2012 | 9756 | 0.090 |
Why?
|
Brain Chemistry | 1 | 2014 | 959 | 0.090 |
Why?
|
Cranial Nerve Neoplasms | 1 | 2011 | 134 | 0.090 |
Why?
|
Demyelinating Diseases | 1 | 2012 | 358 | 0.080 |
Why?
|
Treatment Outcome | 7 | 2017 | 65480 | 0.080 |
Why?
|
Patient Selection | 1 | 2022 | 4265 | 0.080 |
Why?
|
Ventral Thalamic Nuclei | 1 | 2009 | 43 | 0.080 |
Why?
|
Language | 1 | 2019 | 1559 | 0.080 |
Why?
|
Subtraction Technique | 1 | 2012 | 519 | 0.080 |
Why?
|
Medicine, Traditional | 1 | 2009 | 89 | 0.080 |
Why?
|
Tuberculosis, Cutaneous | 1 | 2008 | 17 | 0.080 |
Why?
|
Image Processing, Computer-Assisted | 4 | 2015 | 9080 | 0.080 |
Why?
|
Tuberculosis, Central Nervous System | 1 | 2008 | 17 | 0.080 |
Why?
|
Vagus Nerve | 1 | 2011 | 460 | 0.080 |
Why?
|
Microelectrodes | 1 | 2009 | 308 | 0.080 |
Why?
|
Microscopy | 1 | 2013 | 910 | 0.080 |
Why?
|
Staining and Labeling | 1 | 2012 | 1081 | 0.070 |
Why?
|
Luminescent Measurements | 1 | 2009 | 342 | 0.070 |
Why?
|
ROC Curve | 1 | 2015 | 3629 | 0.070 |
Why?
|
Neurosurgical Procedures | 2 | 2019 | 2110 | 0.070 |
Why?
|
Substantia Nigra | 1 | 2009 | 347 | 0.070 |
Why?
|
Neoadjuvant Therapy | 1 | 2019 | 2909 | 0.070 |
Why?
|
Heme Oxygenase-1 | 1 | 2009 | 364 | 0.070 |
Why?
|
Imaging, Three-Dimensional | 3 | 2014 | 4076 | 0.070 |
Why?
|
Subthalamic Nucleus | 1 | 2009 | 203 | 0.070 |
Why?
|
Brain Diseases | 2 | 2008 | 1558 | 0.070 |
Why?
|
Prognosis | 3 | 2018 | 30046 | 0.070 |
Why?
|
Amnesia, Anterograde | 1 | 2006 | 20 | 0.070 |
Why?
|
Hemoglobins | 1 | 2012 | 1531 | 0.070 |
Why?
|
Neurilemmoma | 1 | 2011 | 524 | 0.070 |
Why?
|
Survival Analysis | 2 | 2015 | 10115 | 0.060 |
Why?
|
Mice, Nude | 1 | 2012 | 3631 | 0.060 |
Why?
|
Encephalitis, Viral | 1 | 2006 | 59 | 0.060 |
Why?
|
Sex Distribution | 1 | 2011 | 2280 | 0.060 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2011 | 1793 | 0.060 |
Why?
|
Herpesvirus 6, Human | 1 | 2006 | 98 | 0.060 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2007 | 3782 | 0.060 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2008 | 664 | 0.060 |
Why?
|
Angiogenesis Inhibitors | 2 | 2012 | 2059 | 0.060 |
Why?
|
Inflammation | 1 | 2023 | 10868 | 0.050 |
Why?
|
Quinazolines | 1 | 2010 | 1373 | 0.050 |
Why?
|
Radiation Injuries | 1 | 2011 | 1203 | 0.050 |
Why?
|
Intensive Care Units | 1 | 2017 | 3800 | 0.050 |
Why?
|
Carcinoma, Basal Cell | 1 | 2008 | 565 | 0.050 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2007 | 618 | 0.050 |
Why?
|
Monitoring, Intraoperative | 1 | 2009 | 950 | 0.050 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2007 | 542 | 0.050 |
Why?
|
Neoplasm Invasiveness | 1 | 2011 | 3629 | 0.050 |
Why?
|
Neoplasm, Residual | 2 | 2020 | 1019 | 0.050 |
Why?
|
Disease Models, Animal | 2 | 2012 | 18354 | 0.050 |
Why?
|
Cerebellar Neoplasms | 1 | 2007 | 591 | 0.050 |
Why?
|
Epidermal Cyst | 1 | 2002 | 63 | 0.050 |
Why?
|
Brain Abscess | 1 | 2002 | 123 | 0.050 |
Why?
|
Lipids | 1 | 2012 | 3345 | 0.050 |
Why?
|
Piperidines | 1 | 2010 | 1667 | 0.050 |
Why?
|
Disease Progression | 2 | 2019 | 13674 | 0.050 |
Why?
|
Aged | 11 | 2020 | 171786 | 0.050 |
Why?
|
Scoliosis | 1 | 2008 | 793 | 0.050 |
Why?
|
Artifacts | 1 | 2009 | 1942 | 0.040 |
Why?
|
Receptors, GABA | 1 | 2022 | 312 | 0.040 |
Why?
|
Decision Trees | 1 | 2022 | 509 | 0.040 |
Why?
|
Models, Neurological | 1 | 2008 | 1782 | 0.040 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2008 | 944 | 0.040 |
Why?
|
Intraoperative Period | 1 | 2020 | 513 | 0.040 |
Why?
|
Neoplasms, Second Primary | 1 | 2007 | 1060 | 0.040 |
Why?
|
Neuroglia | 1 | 2005 | 960 | 0.040 |
Why?
|
Esophageal Neoplasms | 1 | 2008 | 1674 | 0.040 |
Why?
|
Software | 1 | 2012 | 4479 | 0.040 |
Why?
|
Stereotaxic Techniques | 1 | 2020 | 559 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 15471 | 0.040 |
Why?
|
Proteins | 1 | 2012 | 6011 | 0.040 |
Why?
|
Animals | 6 | 2022 | 169335 | 0.030 |
Why?
|
Prospective Studies | 2 | 2022 | 54962 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2010 | 12562 | 0.030 |
Why?
|
alpha-Synuclein | 1 | 2022 | 774 | 0.030 |
Why?
|
Pregnancy | 1 | 2017 | 30265 | 0.030 |
Why?
|
Cell Line, Tumor | 1 | 2012 | 17173 | 0.030 |
Why?
|
Postoperative Period | 1 | 2020 | 1830 | 0.030 |
Why?
|
Cohort Studies | 1 | 2018 | 41808 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2010 | 14794 | 0.030 |
Why?
|
Time Factors | 2 | 2019 | 40261 | 0.030 |
Why?
|
Mice, Inbred C57BL | 1 | 2012 | 22379 | 0.030 |
Why?
|
Hematoxylin | 1 | 2013 | 61 | 0.030 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2013 | 70 | 0.030 |
Why?
|
Enzyme Activation | 1 | 2019 | 3588 | 0.030 |
Why?
|
Mice | 4 | 2013 | 82072 | 0.030 |
Why?
|
Neoplasm Staging | 1 | 2007 | 11262 | 0.030 |
Why?
|
Color | 1 | 2013 | 297 | 0.030 |
Why?
|
Software Validation | 1 | 2012 | 59 | 0.020 |
Why?
|
Functional Laterality | 1 | 2019 | 2267 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2010 | 11886 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2008 | 6401 | 0.020 |
Why?
|
Neoplasms | 1 | 2020 | 22389 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2019 | 59739 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3554 | 0.020 |
Why?
|
Melanoma | 1 | 2008 | 5709 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2013 | 2018 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2008 | 5864 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 2008 | 6982 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2011 | 15889 | 0.020 |
Why?
|
Immune Reconstitution Inflammatory Syndrome | 1 | 2008 | 61 | 0.020 |
Why?
|
Luciferases | 1 | 2009 | 713 | 0.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2006 | 5716 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2010 | 899 | 0.020 |
Why?
|
Diverticulitis | 1 | 2010 | 187 | 0.020 |
Why?
|
Observer Variation | 1 | 2013 | 2623 | 0.020 |
Why?
|
Least-Squares Analysis | 1 | 2007 | 367 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 550 | 0.020 |
Why?
|
Urban Health | 1 | 2008 | 535 | 0.020 |
Why?
|
Mathematical Computing | 1 | 2006 | 142 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2008 | 11230 | 0.020 |
Why?
|
Markov Chains | 1 | 2009 | 979 | 0.020 |
Why?
|
Peru | 1 | 2008 | 891 | 0.020 |
Why?
|
Neurons | 1 | 2005 | 9519 | 0.020 |
Why?
|
Neutropenia | 1 | 2010 | 893 | 0.010 |
Why?
|
Young Adult | 3 | 2019 | 60131 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2008 | 13594 | 0.010 |
Why?
|
Diffusion | 1 | 2006 | 818 | 0.010 |
Why?
|
Drug Synergism | 1 | 2008 | 1762 | 0.010 |
Why?
|
Risk Factors | 1 | 2011 | 74976 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2015 | 5323 | 0.010 |
Why?
|
Pulvinar | 1 | 2003 | 24 | 0.010 |
Why?
|
Laryngeal Neoplasms | 1 | 2007 | 514 | 0.010 |
Why?
|
Meta-Analysis as Topic | 1 | 2008 | 1364 | 0.010 |
Why?
|
Organ Size | 1 | 2008 | 2268 | 0.010 |
Why?
|
Cerebrospinal Fluid | 1 | 2006 | 545 | 0.010 |
Why?
|
Neoplastic Stem Cells | 1 | 2011 | 1356 | 0.010 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2010 | 1126 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2011 | 2395 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 2010 | 1181 | 0.010 |
Why?
|
Wrist | 1 | 2003 | 231 | 0.010 |
Why?
|
HIV Infections | 1 | 2008 | 17591 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2010 | 4862 | 0.010 |
Why?
|
Temporomandibular Joint | 1 | 2003 | 201 | 0.010 |
Why?
|
Treatment Failure | 1 | 2008 | 2664 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2008 | 21188 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2011 | 2634 | 0.010 |
Why?
|
Up-Regulation | 1 | 2009 | 4148 | 0.010 |
Why?
|
Orbit | 1 | 2003 | 459 | 0.010 |
Why?
|
Radiotherapy | 1 | 2007 | 1506 | 0.010 |
Why?
|
Antitubercular Agents | 1 | 2008 | 1397 | 0.010 |
Why?
|
Reference Values | 1 | 2006 | 4940 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2010 | 8559 | 0.010 |
Why?
|
Mycobacterium tuberculosis | 1 | 2008 | 1930 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2009 | 9565 | 0.010 |
Why?
|
Poverty | 1 | 2008 | 2720 | 0.010 |
Why?
|
Artificial Intelligence | 1 | 2011 | 2666 | 0.010 |
Why?
|
United States | 1 | 2024 | 73186 | 0.010 |
Why?
|
Equipment Design | 1 | 2003 | 3530 | 0.010 |
Why?
|
Phantoms, Imaging | 1 | 2003 | 2533 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2008 | 5342 | 0.010 |
Why?
|
Anti-HIV Agents | 1 | 2008 | 4576 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2008 | 8055 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2007 | 4064 | 0.010 |
Why?
|
Biopsy | 1 | 2003 | 6805 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2007 | 6673 | 0.010 |
Why?
|
Cerebral Cortex | 1 | 2006 | 5831 | 0.010 |
Why?
|
Electroencephalography | 1 | 2003 | 6317 | 0.000 |
Why?
|
Child | 1 | 2008 | 80960 | 0.000 |
Why?
|
Adolescent | 1 | 2008 | 89244 | 0.000 |
Why?
|